Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 1/2017

01-01-2017 | Review Paper

Impact of HIV-Status Disclosure on Adherence to Antiretroviral Therapy Among HIV-Infected Children in Resource-Limited Settings: A Systematic Review

Authors: Justin Nichols, Alexis Steinmetz, Elijah Paintsil

Published in: AIDS and Behavior | Issue 1/2017

Login to get access

Abstract

Pediatric HIV remains a significant global health dilemma, especially in resource-constrained nations. As access to ART increases around the world, areas of concern in pediatric HIV treatment include age-appropriate disclosure of HIV status to children and development of adherence habits over time. This review was conducted to synthesize quantitative associations reported between disclosure and adherence among children living with HIV in resource-limited settings. An electronic database search of PubMed, MEDLINE and Cochrane returned 1348 results after removal of duplicates, 14 of which were found to meet inclusion criteria. Review of these reports showed conflicting results regarding the impact of disclosure on adherence, with 5 showing no association, 4 showing a negative impact of disclosure on adherence, and 5 showing positive benefits of disclosure for adherence habits. Thus, there was no clear consensus on the effect, if any, that disclosure has on medication adherence. Longitudinal, prospective research needs to be conducted to evaluate further impacts that disclosure may have on adherence habits over time, and interventions must be structured to link the two processes together in order to maximize health benefit to the child or adolescent.
Literature
1.
2.
3.
4.
5.
Kenu E, Obo-Akwa A, Nuamah GB, Brefo A, Sam M, Lartey M. Knowledge and disclosure of HIV status among adolescents and young adults attending an adolescent HIV clinic in Accra, Ghana. BMC Res Notes. 2014;7:844.CrossRefPubMedPubMedCentral
6.
Barry O, Powell J, Renner L, et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. BMC Infect Dis. 2013;13:476.CrossRefPubMedPubMedCentral
7.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infections. Ann Intern Med. 2000;133(1):21–30.CrossRefPubMed
8.
American Academy of Pediatrics, Comittee on Pediatric AIDS. Disclosure of illness status to children and adolescents with HIV infection. Pediatrics. 1999;103(1):164–6.CrossRef
9.
Pinzon-Iregui MC, Beck-Sague CM, Malow RM. Disclosure of their HIV status to infected children: a review of the literature. J Trop Pediatr. 2013;59(2):84–9.CrossRefPubMed
10.
Tadesse BT, Foster BA, Berhan Y. Cross sectional characterization of factors associated with pediatric HIV status disclosure in Southern Ethiopia. PLoS One. 2015;10(7):e0132691.CrossRefPubMedPubMedCentral
11.
Gerson AC, Joyner M, Fosarelli P, et al. Disclosure of HIV diagnosis to children: when, where, why, and how. J Pediatr Health Care. 2001;15(4):161–7.CrossRefPubMed
12.
Vreeman RC, Gramelspacher AM, Gisore PO, Scanlon ML, Nyandiko WM. Disclosure of HIV status to children in resource-limited settings: a systematic review. J Int AIDS Soc. 2013;16:18466.CrossRefPubMedPubMedCentral
13.
Ferris M, Burau K, Schweitzer AM, et al. The influence of disclosure of HIV diagnosis on time to disease progression in a cohort of Romanian children and teens. AIDS Care. 2007;19(9):1088–94.CrossRefPubMed
14.
Arrive E, Dicko F, Amghar H, et al. HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS One. 2012;7(3):e33690.CrossRefPubMedPubMedCentral
15.
Haberer JE, Cook A, Walker AS, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS One. 2011;6(4):e18505.CrossRefPubMedPubMedCentral
16.
Biressaw S, Abegaz WE, Abebe M, Taye WA, Belay M. Adherence to antiretroviral therapy and associated factors among HIV infected children in Ethiopia: unannounced home-based pill count versus caregivers’ report. BMC Pediatr. 2013;13:132.CrossRefPubMedPubMedCentral
17.
18.
Buchanan AL, Montepiedra G, Sirois PA, et al. Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report. Pediatrics. 2012;129(5):e1244–51.CrossRefPubMedPubMedCentral
19.
Martin S, Elliott-DeSorbo DK, Wolters PL, et al. Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J. 2007;26(1):61–7.CrossRefPubMed
20.
Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet. 2007;370(9581):68–80.CrossRefPubMed
21.
Fetzer BC, Mupenda B, Lusiama J, Kitetele F, Golin C, Behets F. Barriers to and facilitators of adherence to pediatric antiretroviral therapy in a sub-Saharan setting: insights from a qualitative study. AIDS Patient Care STDS. 2011;25(10):611–21.CrossRefPubMedPubMedCentral
22.
Vreeman RC, Nyandiko WM, Ayaya SO, Walumbe EG, Marrero DG, Inui TS. The perceived impact of disclosure of pediatric HIV status on pediatric antiretroviral therapy adherence, child well-being, and social relationships in a resource-limited setting. AIDS Patient Care STDS. 2010;24(10):639–49.CrossRefPubMedPubMedCentral
23.
Bikaako-Kajura W, Luyirika E, Purcell DW, et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav. 2006;10(4):S85–93.CrossRefPubMed
24.
Beck-Sague C, Pinzon-Iregui MC, Abreu-Perez R, et al. Disclosure of their status to youth with human immunodeficiency virus infection in the Dominican Republic: a mixed-methods study. AIDS Behav. 2015;19(2):302–10.CrossRefPubMedPubMedCentral
25.
26.
Seth A, Gupta R, Chandra J, Maheshwari A, Kumar P, Aneja S. Adherence to antiretroviral therapy and its determinants in children with HIV infection—Experience from Paediatric Centre of Excellence in HIV Care in North India. AIDS Care. 2014;26(7):865–71.CrossRefPubMed
27.
Ditekemena J, Luhata C, Bonane W, et al. Antiretroviral treatment program retention among HIV-infected children in the Democratic Republic of Congo. PLoS One. 2014;9(12):e113877.CrossRefPubMedPubMedCentral
28.
Vreeman RC, Nyandiko WM, Liu H, et al. Comprehensive evaluation of caregiver-reported antiretroviral therapy adherence for HIV-infected children. AIDS Behav. 2015;19(4):626–34.CrossRefPubMedPubMedCentral
29.
Blasini I, Chantry C, Cruz C, et al. Disclosure model for pediatric patients living with HIV in Puerto Rico: design, implementation, and evaluation. Dev Behav Pediatr. 2004;25(3):181–9.CrossRef
30.
Beck-Sague CM, Devieux J, Pinzon-Iregui MC, et al. Disclosure of their HIV status to perinatally infected youth using the adapted Blasini disclosure model in Haiti and the Dominican Republic: preliminary results. AIDS. 2015;29(1):S91–8.CrossRefPubMedPubMedCentral
31.
Vreeman RC, Nyandiko WM, Liu H, et al. Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya. J Int AIDS Soc. 2014;17:19227.CrossRefPubMedPubMedCentral
32.
Muller AD, Bode S, Myer L, Stahl J, von Steinbuchel N. Predictors of adherence to antiretroviral treatment and therapeutic success among children in South Africa. AIDS Care. 2011;23(2):129–38.CrossRefPubMed
33.
Medin G, Garcia-Navarro C, Navarro Gomez M, et al. Disease disclosure, treatment adherence, and behavioural profile in a cohort of vertically acquired HIV-infected adolescents. NeuroCoRISpeS study. AIDS Care. 2016;28(1):124–130.CrossRefPubMed
34.
Kang E, Delzell DA, Chhabra M, Oberdorfer P. Factors associated with high rates of antiretroviral medication adherence among youth living with perinatal HIV in Thailand. Int J STD AIDS. 2015;26(8):534–41.CrossRefPubMed
35.
O’Malley G, Beima-Sofie K, Feris L, et al. “If I take my medicine, I will be strong:” evaluation of a pediatric HIV disclosure intervention in Namibia. J Acquir Immune Defic Syndr. 2015;68(1):e1–7.CrossRefPubMed
36.
Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23(11):1035–41.CrossRefPubMed
37.
Ernesto AS, Lemos RM, Huehara MI, Morcillo AM, Dos Santos Vilela MM, Silva MT. Usefulness of pharmacy dispensing records in the evaluation of adherence to antiretroviral therapy in Brazilian children and adolescents. Braz J Infect Dis. 2012;16(4):315–20.CrossRefPubMed
38.
Trajos AM, Reyes L, Bahamon MJ, Alarcon Y, Gaviria G. Effects in the adherence treatment and psychological adjustment after the disclosure of HIV/AIDS diagnosis with the “DIRE” clinical model in Colombian children under 17. Rev Chilena Infectol. 2015;32(4):408–15.CrossRef
39.
John-Stewart GC, Wariua G, Beima-Sofie KM, et al. Prevalence, perceptions, and correlates of pediatric HIV disclosure in an HIV treatment program in Kenya. AIDS Care. 2013;25(9):1067–76.CrossRefPubMed
40.
Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral
41.
Cluver LD, Hodes RJ, Toska E, et al. ‘HIV is like a tsotsi. ARVs are your guns’: associations between HIV-disclosure and adherence to antiretroviral treatment among adolescents in South Africa. AIDS. 2015;29(Suppl 1):S57–65.CrossRefPubMed
42.
Vreeman RC, Scanlon ML, Mwangi A, et al. A cross-sectional study of disclosure of HIV status to children and adolescents in western Kenya. PLoS One. 2014;9(1):e86616.CrossRefPubMedPubMedCentral
43.
Nabukeera-Barungi N, Kalyesubula I, Kekitiinwa A, Byakika-Tusiime J, Musoke P. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann Trop Paediatr. 2007;27(2):123–31.CrossRefPubMed
44.
Arage G, Tessema GA, Kassa H. Adherence to antiretroviral therapy and its associated factors among children at South Wollo Zone Hospitals, Northeast Ethiopia: a cross-sectional study. BMC Public Health. 2014;14:365.CrossRefPubMedPubMedCentral
45.
Dachew BA, Tesfahunegn TB, Birhanu AM. Adherence to highly active antiretroviral therapy and associated factors among children at the University of Gondar Hospital and Gondar Poly Clinic, Northwest Ethiopia: a cross-sectional institutional based study. BMC Public Health. 2014;14:875.CrossRefPubMedPubMedCentral
46.
Biadgilign S, Deribew A, Amberbir A, Deribe K. Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia. BMC Pediatr. 2008;8:53.CrossRefPubMedPubMedCentral
47.
Polisset J, Ametonou F, Arrive E, Aho A, Perez F. Correlates of adherence to antiretroviral therapy in HIV-infected children in Lome, Togo, West Africa. AIDS Behav. 2009;13(1):23–32.CrossRefPubMed
48.
49.
Bhattacharya M, Dubey AP, Sharma M. Patterns of diagnosis disclosure and its correlates in HIV-Infected North Indian children. J Trop Pediatr. 2011;57(6):405–11.CrossRefPubMed
50.
Turissini ML, Nyandiko WM, Ayaya SO, et al. The prevalence of disclosure of HIV status to HIV-infected children in Western Kenya. J Pediatric Infect Dis Soc. 2013;2(2):136–43.CrossRefPubMed
51.
Sirikum C, Sophonphan J, Chuanjaroen T, et al. HIV disclosure and its effect on treatment outcomes in perinatal HIV-infected Thai children. AIDS Care. 2014;26(9):1144–9.CrossRefPubMed
52.
Metadata
Title
Impact of HIV-Status Disclosure on Adherence to Antiretroviral Therapy Among HIV-Infected Children in Resource-Limited Settings: A Systematic Review
Authors
Justin Nichols
Alexis Steinmetz
Elijah Paintsil
Publication date
01-01-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1481-z

Other articles of this Issue 1/2017

AIDS and Behavior 1/2017 Go to the issue

Original Paper

The “Safe Sex” Conundrum: Anticipated Stigma From Sexual Partners as a Barrier to PrEP Use Among Substance Using MSM Engaging in Transactional Sex

Original Paper

How Does Stigma Affect People Living with HIV? The Mediating Roles of Internalized and Anticipated HIV Stigma in the Effects of Perceived Community Stigma on Health and Psychosocial Outcomes

Substantive Review

Criminalization of HIV Exposure: A Review of Empirical Studies in the United States

Substantive Review

Understanding HIV-Related Stigma Among Women in the Southern United States: A Literature Review

Original Paper

Proximate Context of HIV-Related Stigma and Women’s Use of Skilled Childbirth Services in Uganda

Original Paper

Stigma, Facility Constraints, and Personal Disbelief: Why Women Disengage from HIV Care During and After Pregnancy in Morogoro Region, Tanzania
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits